T1	Participants 577 860	171 children with standard-risk ALL, age 1 to 9.99 years at diagnosis, previously randomly assigned to IT methotrexate (n = 82) or to triple IT therapy (n = 89) on CCG 1952, underwent neurocognitive evaluation by a licensed psychologist at a mean of 5.9 years after random assignment
T2	Participants 870 907	Patients who received IT methotrexate
T3	Participants 1141 1187	19.5% of children in the IT methotrexate group
T4	Participants 1322 1331	the group
